Busser B - Search Results

1

Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications.

Busser B, Lupo J, Sancey L, Mouret S, Faure P, Plumas J, Chaperot L, Leccia MT, Coll JL, Hurbin A, Hainaut P, Charles J. Busser B, et al. Biomed Res Int. 2017;2017:5986129. doi: 10.1155/2017/5986129. Epub 2017 Apr 6. Biomed Res Int. 2017. PMID: 28484715 Free PMC article. Review.

2

Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.

Busser B, Sancey L, Josserand V, Niang C, Favrot MC, Coll JL, Hurbin A. Busser B, et al. Mol Ther. 2010 Mar;18(3):528-35. doi: 10.1038/mt.2009.226. Epub 2009 Oct 13. Mol Ther. 2010. PMID: 19826406 Free PMC article.

3

Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.

Busser B, Sancey L, Josserand V, Niang C, Khochbin S, Favrot MC, Coll JL, Hurbin A. Busser B, et al. Mol Ther. 2010 Mar;18(3):536-43. doi: 10.1038/mt.2009.227. Epub 2009 Oct 13. Mol Ther. 2010. PMID: 19826407 Free PMC article.

4

Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.

Hurbin A, Wislez M, Busser B, Antoine M, Tenaud C, Rabbe N, Dufort S, de Fraipont F, Moro-Sibilot D, Cadranel J, Coll JL, Brambilla E. Hurbin A, et al. Among authors: busser b. J Pathol. 2011 Sep;225(1):83-95. doi: 10.1002/path.2897. Epub 2011 May 19. J Pathol. 2011. PMID: 21598249 Clinical Trial.

5

The multiple roles of amphiregulin in human cancer.

Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A. Busser B, et al. Biochim Biophys Acta. 2011 Dec;1816(2):119-31. doi: 10.1016/j.bbcan.2011.05.003. Epub 2011 May 30. Biochim Biophys Acta. 2011. PMID: 21658434 Review.

6

Unusual increased beta-globulins in an elderly patient.

Busser B, Millet S, Bulabois CE, Faure P, Renversez JC. Busser B, et al. Clin Chem. 2011 Jul;57(7):948-51. doi: 10.1373/clinchem.2010.150425. Clin Chem. 2011. PMID: 21712550 No abstract available.

7

Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma.

Busser B, Leccia MT, Gras-Combe G, Bricault I, Templier I, Claeys A, Richard MJ, de Fraipont F, Charles J. Busser B, et al. JAMA Dermatol. 2013 Dec;149(12):1403-6. doi: 10.1001/jamadermatol.2013.8198. JAMA Dermatol. 2013. PMID: 24108467

8

The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.

Jeannot V, Busser B, Brambilla E, Wislez M, Robin B, Cadranel J, Coll JL, Hurbin A. Jeannot V, et al. Among authors: busser b. Int J Cancer. 2014 Jun 1;134(11):2560-71. doi: 10.1002/ijc.28594. Epub 2013 Dec 13. Int J Cancer. 2014. PMID: 24374738

9

Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.

Charles J, Beani JC, Fiandrino G, Busser B. Charles J, et al. Among authors: busser b. J Am Acad Dermatol. 2014 Sep;71(3):e97-9. doi: 10.1016/j.jaad.2014.03.038. J Am Acad Dermatol. 2014. PMID: 25128147 Free article. No abstract available.

10

[Mechanisms of resistance to anti-BRAF treatments].

Charles J, Martel C, de Fraipont F, Leccia MT, Robert C, Busser B. Charles J, et al. Among authors: busser b. Ann Dermatol Venereol. 2014 Nov;141(11):671-81. doi: 10.1016/j.annder.2014.06.021. Epub 2014 Aug 7. Ann Dermatol Venereol. 2014. PMID: 25442471 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters